ClinicalTrials.gg
CompletedNCT00544869Updated Jan 30, 2014Results posted

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

A Phase 3 interventional study of OPC-41061 (Tolvaptan) in Cardiac Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-01-30.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Study summary

To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day if diuretic effect is insufficient (treatment period 2) in congestive heart failure (CHF) patients with extracellular volume expansion despite conventional diuretic therapy.

02

Conditions studied

  • Cardiac Edema

Keywords

  • Vasopressin antagonist , Cardiac Edema ,Diuretics
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with cardiac edema receiving diuretic treatment since 7 days prior to the commencement of study drug administration.
  2. Subjects receiving one of the following diuretic treatments since 3 days prior to the commencement of study drug administration without changing the dose or dosing regimen (including subjects scheduled to start treatment during the run-in observation period).

      1. A loop diuretic at a daily dosage equivalent to 40 mg or more of furosemide
      1. Concomitant administration of a loop diuretic and a thiazide diuretic (at any doses)
      1. Concomitant administration of a loop diuretic and an anti-aldosterone drug (at any doses)
  3. CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion.
  4. Male or female subjects between the ages of 20 and 85, inclusive (at time of )
  5. Subjects able to stay at the study site from the day before the start of the run-in observation period until completion of post-treatment observation 2 (7 to 10 days after final study drug administration)
  6. Subjects capable of giving informed consent to participate in the study of their own free will

Exclusion criteria

Exclusion Criteria:

  1. Heart failure patients with markedly fluctuating symptoms
  2. Patients with an assisted circulation device
  3. Patients with any of the following complications or symptoms:

      1. Suspected decrease in circulatory blood flow ,
      1. Hypertrophic cardiomyopathy (other than dilated phase),
      1. Cardiac valve disease with significant heart valve stenosis,
      1. Hepatic coma
  4. Patients who develop acute myocardial infarction within 30 days prior to the screening examination
  5. Patients with a definite diagnosis of active myocarditis or amyloid cardiomyopathy
  6. Subjects with any of the following complications or symptoms:

      1. Poorly controlled diabetes melllitus,
      1. Anuria,
      1. Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  7. Subjects with any of the following disease histories:

      1. Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in subjects without an implanted defibrillator,
      1. Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction),
      1. A history of or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
  8. Subjects who are severely obese [ (BMI, body weight (kg)/height (m)2] exceeding 35]
  9. Subjects with systolic blood pressure in the decubitus position exceeding 90 mmHg
  10. Subjects with any of the following abnormal laboratory values:

      1. Total > 3.0 mg/dL,
      1. serum creatinine > 3.0 mg/dL,
      1. serum sodium > 147 mEq/L,
      1. serum potassium > 5.5 mEq/L
  11. Patients who are unable to take oral medication
  12. Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant during the study period
  13. Subjects who received any drug other than OPC-41061 within 30 days prior to the screening examination
  14. Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    1

    Drug: OPC-41061 (Tolvaptan)

Interventions

06

What researchers measure

Primary outcomes

  1. Body Weight

    The change of body weight from baseline at final observation

    Time frame: Baseline, Day 14 or at the time of final drug administration

07

Results

Posted Jan 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneStopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/Day
Started36142
Completed24122
Not completed1220
Withdrew: Rsolution of congenitive symptoms300
Withdrew: Adverse event610
Withdrew: Lack of efficacy110
Withdrew: Physician decision200

Outcome measures

PrimaryBody Weight

The change of body weight from baseline at final observation

Time frame:
Baseline, Day 14 or at the time of final drug administration
Reported as:
Mean · Kg
Body Weight
KgStopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/Day
Body Weight-2.05 ± 1.86-1.31 ± 2.95-2.9 ± 2.69

Adverse events

Collected over 7 Days for stopped at end of treated period 1 group 14 Days for continued at 15 or 30 mg/day group. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stopped at End of Treatment Period 1—3/36 (8.3%)30/36 (83.3%)
Continued at 15 mg/Day—1/13 (7.7%)12/13 (92.3%)
Dose Escalated to 30 mg/Day—0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventStopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/Day
Cardiac FailureCardiac disorders0/361/130/2
Intracardiac ThrombusCardiac disorders1/360/130/2
Cerebral Artery EmbolismNervous system disorders1/360/130/2
Renal Failure ChronicRenal and urinary disorders1/360/130/2
Most frequent other events
Showing 10 of 36
Most frequent other events
EventStopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/Day
Ventricular TachycardiaCardiac disorders4/360/131/2
Blood Alkaline Phosphatase IncreasedInvestigations0/360/131/2
Blood Creatinine IncreasedInvestigations4/364/131/2
Blood Urea IncreasedInvestigations6/364/131/2
Blood Uric Acid IncreasedInvestigations6/364/131/2
HyperlipidaemiaMetabolism and nutrition disorders0/360/131/2
ThirstGeneral disorders14/366/130/2
Blood Glucose IncreasedInvestigations4/364/130/2
Blood Potassium IncreasedInvestigations3/363/130/2
EpistaxisRespiratory, thoracic and mediastinal disorders1/363/130/2

Baseline characteristics

1 Subject of Arm "Continued at 15 mg/day" was excluded from analysis because of GCP incompliance

Age, Categorical
Age, Categorical(Participants)Stopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/DayTotal
<=18 years0000
Between 18 and 65 years74011
>=65 years299240
Age, Continuous
Age, Continuous(years)Stopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/DayTotal
Mean71.3 ± 9.567.2 ± 12.778.5 ± 2.170.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Stopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/DayTotal
Female112114
Male2511137
Region of Enrollment
Region of Enrollment(participants)Stopped at End of Treatment Period 1Continued at 15 mg/DayDose Escalated to 30 mg/DayTotal
Japan3613251
08

Study locations

6 sites
  • Chubu region, Japan
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyuush, Japan
  • Shikoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2007
First posted
Oct 16, 2007
Start
Oct 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Jan 30, 2014
Last update
Jan 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00544869
Responsible party
Sponsor
First posted
Oct 16, 2007
Start date
Oct 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Jan 30, 2014
Last update
Jan 30, 2014

Study contacts

Katsuhisa Saito
study director · Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion